TTA Startups Led by the Ministry of Science and Technology Won 125 Million USD Business Opportunities during the MedTech Conference 2019
Under the initiative of the Ministry of Science and Technology (MOST) of Taiwan, Taiwan Tech Arena (TTA) led 12 startups that have some of the best minds in medical technology to Boston. By showcasing their innovative tech solutions during the MedTech Conference 2019 (23-25, Sept.) and TTA Demo Day (27, Sept.), those startups had gained 125 million USD equivalent business opportunities.
At the opening ceremony
of TTA Pavilion, Director General Hsu from Taipei Economic and Cultural Office in Boston first welcomed all startup teams to Boston, and indicated that Boston is an important base for the global medical technology and life science industry. There are 16 of the world's top 20 pharmaceutical companies established here, including Novartis's laboratory, the world's leading pharmaceutical company, and GE with a large scale of bio-business also have moved to Boston.
“The AdvaMed is the most important association in the global medical technology industry, with highly professional associated companies, new startups and multinational corporations. Since Taiwan’s medical technology industry technology is quite standard, he believed that it can expand the global medical market and create more business opportunities in this Conference.” Said Ralph F. Ives, the Executive Vice President of AdvaMed (host of the MedTech Conference).
The MOST also mentioned that it has initiated TTA to assist domestic talents in connecting with the global startup ecosystems and has established a mutually beneficial partnership to create opportunities for Taiwan’s entrepreneurs to enter the overseas markets. The MOST expects to engage with international resources and investors via participating in important global events.
TTA Startups Drew Attentions from the World
The MedTech Conference is hosted by AdvaMed, the event involves 80 international medical-related companies and 400 key industry members to create important influence of MedTech in the global market. TTA’s 12 medical startups have drawn attentions in the exhibition.
Heroic-Faith Medical Science Co., Ltd. demonstrated its latest artificial intelligence combined with respiratory monitoring during the show, and was approved by the US Food and Drug Administration FDA, the American College of Anesthesiology, the American Dental Association, and the US Military Medical Unit. Respiratory monitoring, voice recognition and other functions obtained its clinical trial and business cooperation.
APrevent Medical Inc.'s postoperative adjustable throat implant obtained the global pathway cooperation with Japanese medical materials.
FaceHeart Inc.'s AI face recognition detection Heartbeat technology collaborated with HP's photography identification and Qiaoshan Health Equipment's cloud-based smart system.
Summed Taiwan Inc.'s medical catheter and wound patch platform reached an early stage cooperation opportunity with international giants Terumo, Academic Institutions University of Pittsburgh and University of Massachusetts during the exhibition.
Taipei Economic and Cultural Office in Boston First Held TTA Demo Day to Introduce Boston’s Med-Tech Investment Ecosystem
In order to introduce med-tech investment ecosystem in Boston, Taipei Economic and Cultural Office in Boston held TTA Demo Day on 27th. TTA’s startups showcased their innovative med-tech to representatives from MPM Capital Founder, Flare Capital Partners, Alira Health, Leading Business Ventures, and Medtronic. In addition, there was also a panel discussion on “Boston’s Innovation Ecosystem and Strategies for International Startups to Integrate” held during the event; the Panel discussion had attracted more than 100 participants.
TTA, Empowering Tech Startups
TTA not only aims to connect Taiwanese startups with global startup ecosystems, but also promotes development of AI, software, and semiconductor in med-tech. Through participating in global events, TTA’s startups can draw attentions from investors and will have more chance to collaborate with global biomedical ecosystems.